Targeting interleukin-2 as a treatment for psoriasis

Current Opinion in Investigational Drugs

Volumn 2, Issue 11, 2001, Pages 1546-1548

  Salim, A ^a   Emerson, R ^a  

^a UNIVERSITY HOSPITAL OF NORTH STAFFORDSHIRE   (United Kingdom)

Author keywords

Cyclosporin; IL 2; Macrolactams; Monoclonal antibodies; Psoriasis; T cells

Indexed keywords

ANTIPSORIASIS AGENT; ASCOMYCIN; CYCLOSPORIN; CYCLOSPORIN A; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ANTIBODY; PIMECROLIMUS; TACROLIMUS;

CLINICAL TRIAL; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DOSAGE FORM; DRUG EFFICACY; DRUG TARGETING; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; MALIGNANT TRANSFORMATION; NEPHROTOXICITY; NONHUMAN; PATHOPHYSIOLOGY; PSORIASIS; REVIEW; T LYMPHOCYTE ACTIVATION;

ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-2; PSORIASIS; RECEPTORS, INTERLEUKIN-2;

EID: 0035187939     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. HLA region genes and immune activation in the pathogenesis of psoriasis
2. Psoriasis, T cell and autoimmunity
3. Expression of HLA-DR molecules by keratinocytes, and presence of Langerhans cells in the dermal infiltrate of active psoriatic plaques
4. Interleukin 2 and psoriasis
5. Soluble interleukin-2 receptor (sIL-2R) is a marker of disease activity in proriasis: A comparison of sIL-2R, sCD27, sCD4, sCD8, and sICAM-1
6. Cell contribution in antibody response
7. Biologic effects of Cyclosporin A: A new antilymphocytic agent
8. Cyclosporin for psoriasis
9. A systematic review of treatments for severe psoriasis
10. Renal biopsy findings in longterm cyclosporin treatment of psoriasis
11. Clinical aspects of cyclosporin nephrotoxicity
12. Efficacy and pharmacokinetics of two formulations of cyclosporine A in patients with psoriasis
13. Combination treatment with methotrexate and cyclosporin for severe recalcitrant psoriasis
14. Treatment of psoriasis with intermittent short course cyclosporin (Neoral). A multicentre study
15. B-cell lymphoma developing in a patient on cyclosporin for recalcitrant psoriasis
16. The pathology of post-transplant lymphoproliferative disorder occurring in the setting of cyclosporine A prednisone immunosuppression
17. Epstein-Barr virus-induced B-cell lymphoma after renal transplantation
18. SDZ ASM 981: An emerging safe and affective treatment for atopic dermatitis
19. A short term trial of tacrolimus ointment for atopic dermatitis
20. SDZ ASM 981 is effective for psoriasis when used topically under occlusion
21. Systemic tacrolimus (FK 506) is effective for the treatment of psoriasis in a double-blind, placebo-controlled study. The European FK 506 Multicentre Psoriasis Study Group
22. Clinical experience with oral SDZ ASM 981 in psoriasis
23. Ascomycin: An advance in the management of atopic dermatitis
24. Immunoprophylaxsis with a monoclonal anti-IL-2 receptor antibody in liver transplant patients
25. Randomised trial of Simulect versus placebo for control of acute cellular rejection in renal allograft recipients
26. Prolonged action of a chimeric IL-2 receptor (CD25) monoclonal antibody used in cadeveric renal transplantation
27. Successful treatment of severe generalized pustular psoriasis with basiliximab (IL-2 receptor blocker)
28. Successful treatment of severe psoriasis with basiliximab, an interleukin-2 receptor monoclonal antibody
29. Reduction of acute renal allograft rejection by daclizumab
30. Treatment of recalcitrant psoriasis with daclizumab
31. Use of a chimeric monoclonal anti-CD4 antibody in patients with refractory rheumatoid arthritis